Quote:
Originally Posted by kiwi33
Hi DejaVu
Thanks for that - I had not come across BI 655066 or Stelara before.
Coming back to the NEJM paper. I would have been inclined to split the subjects into four groups (at random and double-blind of course).
Group 1 would get placebo 1 and placebo 2. Group 2 would get guselkumab and placebo 1. Group 3 would get adalimumab and placebo 1. Group 4 would get guselkumab and adalimumab.
The point is that maybe some people with psoriasis will be helped more by both guselkumab and adalimumab (different targets) - Group 4 compared to Groups 2 and 3 - than either in isolation. That could make a difference.
Progressing psoriatic arthritis is not one of my health issues but I hope that you are getting good care  .
Kiwi |
Hi Kiwi,
I see great value in the way you would have split up the groups.
I wonder if a similar study will occur in the future, as researchers get further into the use of guselkumab.
These studies are on how these drugs affect Plaque Psoriasis and not (yet) about how they affect Psoriatic Arthritis. I try to follow the research anyway.
Sometimes, some of these psoriasis drugs are later used in Psoriatic Arthritis.
Many people do not realize psoriatic conditions are "systemic" with known co-morbidities. (Similar to Rheumatoid arthritis in raising havoc with organs, etc. Yet, also different from Rheumatoid arthritis.)
Fortunately for me, my Psoriatic Arthritis (aka PsA) is slowly progressive. It's often extremely painful nonetheless. My rheumatologist is extremely bright and able to fully comprehend the complexities of the multiple co-occurring diagnoses in my case, which is truly complicated. She is great at thinking outside of the box and keeps me "safe," as there are some major contraindications to my attempting some of the drugs.
Thanks again for your feedback!
Warmly,
DejaVu